Global Etanercept Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Etanercept Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Etanercept market finds that the global Etanercept market reached a value of USD 6270.0 million in 2022. It’s expected that the market will achieve USD 6566.0 million by 2028, exhibiting a CAGR of 0.77% during the forecast period.

Market competition risk, Fierce Competition from anti TNF Therapies

If the technology investment cannot be guaranteed in the future, or the technological leading position of the proposed product cannot be guaranteed, or the new product is not fully accepted by the market, or the current product is invaded by the competitive product, or the current product targets a more effective alternative treatment Programs or drugs, business prospects could be significantly adversely affected.
At the same time, if other companies develop similar drugs prior to research and development, or are more successful in industrialization, marketing, etc., they will face greater market competition risks, and their operating and profitability may be adversely affected.
Anti-TNF therapy forms a certain competition in the Enbrel market.

Resident income and medical ability to pay

With the development of China's economy, the per capita disposable income of residents has continued to increase. Follow With the increase in China's residents' ability to pay for health care, the ability to consume drugs is expected to be further improved.

Industrial policy brings new opportunities

Starting from the State Council's Opinions on Deepening the Reform of the Medical and Health System in March 2009, various departments have successively introduced policies, plans and other measures to gradually establish and improve a basic medical and health system covering urban and rural residents and a new rural cooperative medical system. To gradually provide basic public health services such as disease prevention and control, maternal and child health care, and health education to urban and rural residents, thereby comprehensively improving national health and medical standards.

Region Overview:

North America dominated the Etanercept market in 2022, with a market share of 62.48%.

Company Overview:

Amgen is one of the major players operating in the Etanercept market, holding a share of 63.9% in 2019.

Amgen

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Segmentation Overview:

As for product types, the Enbrel segment held the largest market share in 2022.

Application Overview:

By application, the Rheumatoid Arthritis segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Etanercept market covered in Chapter 3:

Sandoz
Samsung Bioepis
Amgen
Pfizer

In Chapter 4 and Chapter 14.2, on the basis of types, the Etanercept market from 2018 to 2029 is primarily split into:

Enbrel
Benepali
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Etanercept market from 2018 to 2029 covers:

Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis (JIA)
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)